Elevation Oncology, Inc. (ELEV)

Market Cap	178.06M
Revenue (ttm)	n/a
Net Income (ttm)	-45.70M
Shares Out	48.65M
EPS (ttm)	-1.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,762,432
Open	3.790
Previous Close	3.850
Day's Range	3.590 - 4.060
52-Week Range	0.363 - 5.890
Beta	1.36
Analysts	Strong Buy
Price Target	7.25 (+96.48%)
Earnings Date	May 13, 2024

About ELEV

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: ELEV

Analyst Forecast

According to 4 analysts, the average rating for ELEV stock is "Strong Buy." The 12-month stock price forecast is $7.25, which is an increase of 96.48% from the latest price.

Price Target

$7.25

(96.48% upside)

Analyst Consensus: Strong Buy